Jefferies has maintained its buy rating on Sun Pharma with a target price of ₹2,070 after a recent management meeting, highlighting the company’s strategy of balancing growth in India with expansion in specialty products.
The brokerage said Sun Pharma continues to focus on volume growth and differentiated offerings in the domestic market, with GLP drugs seen as a key opportunity in the coming years. Its specialty business has been a key margin driver over the past five years, though new launches such as Leqselvi and Unloxcyt are expected to have minimal revenue contribution in FY26 due to higher selling, general and administrative expenses.
To strengthen its manufacturing footprint, Sun Pharma has planned a new plant in India, which will help de-risk operations from its existing Halol and Mohali facilities. Jefferies believes these steps reinforce the company’s long-term growth potential and provide stability against regulatory risks.
Disclaimer: The views and recommendations made in this article are those of Jefferies. This article does not constitute investment advice. Investors should consult their financial advisors before making any investment decisions.
